This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Seventh Sense Biosystems Receives CE Mark Approval For Its Touch Activated Phlebotomy Blood Collection And Testing System

CAMBRIDGE, Mass., Nov. 4, 2013 /PRNewswire/ -- Seventh Sense Biosystems, Inc., the leading developer of painless blood collection and diagnostic platforms, today announced it has obtained CE Mark approval for its Touch Activated Phlebotomy (TAP™) platform for blood collection and testing.

"This first regulatory approval is a significant milestone in our goal of expanding the reach of blood-based point-of-care diagnostics to a majority of patients, regardless of geography or setting," said Howard Weisman, CEO and President of Seventh Sense. "When fully commercialized, the TAP platform will incorporate additional capabilities for sample separation as well as dried blood spot and on-board diagnostic capabilities."

Studies show that a positive patient experience is closely linked to compliance with a prescribed treatment. Seventh Sense will be developing and commercializing novel diagnostic tools that are specially engineered to eliminate the pain and anxiety that can prevent patients from receiving appropriate care. The company's proprietary innovations in microneedle and microfluidic technology enable the collection of a stable, secure and high quality blood sample without painful lancing or the need for highly skilled medical personnel.

"We've surveyed patients and their physicians around the world and found a significant need for near painless, simple-to-use, and reliable blood collection and diagnostic devices that has so far been unmet," said Weisman.

The company plans to scale-up manufacturing capability in 2014 and continue the development of follow-on products for patients and clinicians in the Americas, Europe and Asia-Pacific regions.

About the Touch Activated Phlebotomy DeviceTouch Activated Phlebotomy (TAP™) is a proprietary platform that draws capillary blood in a painless, one-step process without having to access a vein and it can be utilized across and integrated with a broad spectrum of diagnostic applications. The TAP system penetrates the uppermost layers of skin through the use of micro-needles, collects capillary blood using a novel microfluidic extraction process, and stabilizes the blood with anticoagulant if required. The device has a visual indicator to confirm that collection is complete. The TAP platform is designed for fully automated, high throughput manufacturing.

About Seventh Sense Biosystems, Inc.Founded in 2008, within Flagship VentureLabs™, Seventh Sense is developing an array of products based on the company's proprietary Touch Activated Phlebotomy (TAP™) painless blood collection platform, with an initial focus on enabling important diagnostic testing at the point of care by reducing the discomfort, anxiety and hassle of blood sample collection.  Seventh Sense is backed by leading investors Flagship Ventures and Polaris Partners.  For more information, please visit www.7sbio.com.

For media inquiries contact: Tim Richards617-547-7246  ext. 222 info@7sbio.com

 

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,122.01 +15.31 0.09%
S&P 500 2,000.12 +0.10 0.00%
NASDAQ 4,569.6210 -1.0160 -0.02%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs